Eli Lilly targets alleged black market sales of its experimental GLP-1 drug
Eli Lilly is suing six entitles that it alleges are selling black market versions of its experimental weight loss drug retatrutide. Lilly's lawsuits target U.S.
Reported by 2 outlets — The Hill, MarketWatch. See all sources ↓
Eli Lilly is suing six entitles that it alleges are selling black market versions of its experimental weight loss drug retatrutide. Lilly's lawsuits target U.S. entities selling illegal retatrutide products, including compounding pharmacies, medical spas and online sellers that sell retatrutide as a weight-loss "hack." Those entities falsely claim their drugs are for “research-use only”...
Read the full report at The Hill ↗
Why it matters
2 outlets are covering this world story — one to watch as reporting develops.
- What's the story?
- Eli Lilly is suing six entitles that it alleges are selling black market versions of its experimental weight loss drug retatrutide. Lilly's lawsuits target U.S.
- How widely is it covered?
- 2 outlets, average source rating 7.0/10.
- When was it last updated?
- 4m ago.
How outlets are framing the same story
Here's how each outlet is covering the story — compare their headlines and timing at a glance.
- Coverage card2 outlets1CoverageScouting report
Eli Lilly is suing pharmacies and peptide vendors over sale of its next big weight-loss drug: retatrutide
Sources2TypeCoverageThe Hill
MarketWatch